-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab says EU approves Tepkinly combo for relapsed or refractory follicular lymphoma

PUBT·07/06/2026 17:45:27
Listen to the news
Genmab says EU approves Tepkinly combo for relapsed or refractory follicular lymphoma
  • European Commission granted marketing authorization for Tepkinly (epcoritamab) with lenalidomide, rituximab in relapsed or refractory follicular lymphoma.
  • Phase 3 EPCORE FL-1 showed 79% lower risk of progression or death vs R2 alone; overall response rate 96%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 202607061345BIZWIRE_USPR_____20260618_BW185615) on July 06, 2026, and is solely responsible for the information contained therein.